The short version of RP-HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-11. Anything still debated is marked as such rather than presented as settled.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
| Property | Value | Notes |
|---|---|---|
| Storage temperature, powder | -20 °C or lower | Protect from light and moisture |
| Storage temperature, reconstituted | 2-8 °C | Use within days |
| Purity testing | Reversed-phase HPLC | Separates truncation products |
| Mass confirmation | Mass spectrometry | Detects deamidation and oxidation |
| Common salt forms | Acetate or trifluoroacetate | Affects solubility and weighing |
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
== Regulatory status == The regulatory status of theanine varies by country. It is sold as a dietary supplement across the United States and European Union. In Japan, L-theanine has been approved for use in all foods, with some restrictions in the case of infant foods. In the United States, the FDA considers it to be generally recognized as safe (GRAS) and allows its use as an ingredient in foods and beverages up to a maximum of 250 mg per serving. In 2003, the German Federal Institute for Risk Assessment (Bundesinstitut für Risikobewertung, BfR), an agency of their Federal Ministry of Food and Agriculture, objected to the addition of isolated theanine to beverages. While it was estimated the quantity of green tea consumed by the average Japanese tea drinker per day contains about 20 mg of the substance, there were no studies measuring the amount of theanine being extracted by typical preparation methods, or the percentage lost by discarding the first infusion. Therefore, with the Japanese being exposed to possibly much less than 20 mg per day, it was the opinion of the BfR that pharmacological reactions to drinks typically containing 50 mg of theanine per 500 milliliters could not be excluded –reactions such as impairment of psychomotor skills and amplification of the sedating effects of alcohol and hypnotics.
Avutometinib/defactinib, sold under the brand name Avmapki Fakzynja Co-Pack, is a co-packaged medication used for the treatment of ovarian cancer. It contains the anti-cancer medications avutometinib, a kinase inhibitor, as the potassium salt; and defactinib, a kinase inhibitor, as the hydrochloride. It is taken by mouth. The most common adverse reactions including laboratory abnormalities, include increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count. Avutometinib/defactinib was approved for medical use in the United States in May 2025. The US Food and Drug Administration considers it to be a first-in-class medication.
=== Instability === A 2021 Federal Reserve review of the bank found several deficiencies in its risk management procedures. The bank failed to fix six citations issued by the Fed and was placed under a full supervisory review in July 2022. In the autumn, San Francisco Fed officials met with SVB senior leaders to discuss the bank's ability to raise cash in a crisis and possible exposure to losses as interest rates rose. Fed officials determined the bank was using flawed models that led SVB officers to incorrectly believe rising interest rates would increase the bank's interest revenue to substantially stabilize its financial condition. By early 2023, the Fed placed SVB in a "horizontal review" of its risk management procedures. In the week before the collapse, Moody's Investors Service reportedly informed SVB Financial, the bank's holding company, that it was facing a potential double-downgrade of its credit rating because of its unrealized losses. On March 8, 2023, SVB announced it had sold over $21 billion worth of its investments, borrowed $15 billion, and would hold an emergency sale of its stock to raise $2.25 billion, including $500 million to General Atlantic. JPMorgan Chase and Bank of America turned down opportunities to acquire the bank. Despite the steps taken by the bank, Moody's downgraded SVB on March 8.
Sources: en.wikipedia.org
== Assault charge == In August 2011, Hibbered was charged with assault after he punched and knocked a man out in Mornington on 31 July. He pleaded guilty to the charges in September and escaped conviction, but received a $2500 fine.
It was a formidable fighting force consisting of 1,487 tanks, 1,384 infantry fighting vehicles, 568 artillery pieces, 132 MLRS, 8 missile launchers, and 242 attack helicopters. It had a total troop strength of 146,321 troops. Its primary full strength fighting formations were the 1st Armored Division (United States), the 3rd Armored Division (United States) and the 1st Infantry Division (United States). The 2nd Armored Division (Forward) was assigned to the 1st Infantry Division as its third maneuver brigade. Its Task Force 1-41 Infantry would be the spearhead of VII Corps. In addition, the corps had the 2nd Cavalry Regiment (United States) to act as a scouting and screening force, and two further heavy divisions, the 1st Cavalry Division (United States) and the United Kingdom's 1st Armoured Division, as well as the U.S. 11th Aviation Group. VII Corps fought a number of large battles against Iraqi forces, with some of historic scope and size. Three of the battles at Norfolk, Medina Ridge, and 73 Easting are considered among the largest tank battles in history. By the end of combat operations on 28 February 1991, U.S. VII Corps had driven 260 kilometres (160 mi), captured 22,000 Iraqi soldiers, and destroyed 1,350 Iraqi tanks, 1,224 armored personnel carriers, 285 artillery pieces, 105 air defense systems, and 1,229 trucks.
=== Bi–Bo === Klaus Biemann (1926–2016). Austrian chemist at MIT, the "father of organic mass spectrometry" and particularly noted for his role in advancing protein sequencing with tandem mass spectrometry. Member Natl. Acad. Sci. USA. Ethel Ronzoni Bishop (1890–1975). American biochemist and physiologist at Washington University in St. Louis who studied carbohydrate metabolism. Pamela J. Bjorkman (b. 1956). American biochemist at Caltech, who studies immune recognition of viral pathogens. Member Natl. Acad. Sci. USA. Elizabeth Blackburn AC FRS FAA FRSN (b. 1948). Australian-American biochemist, Nobel Laureate, co-discoverer of telomerase. Konrad Emil Bloch FRS (1912–2000). German-American biochemist at Harvard, who worked on the mechanism and regulation of cholesterol and fatty acid metabolism. Nobel Prize in Physiology or Medicine 1964. Elkan Blout (1919–2006). American biochemist at Harvard, who worked on peptide structure and conformation, including cyclic peptides. Member Natl. Acad. Sci. USA. David Mervyn Blow FRS (1931–2004). British X-ray crystallographer at Imperial College London, who worked on protein structure. Tom Blundell, FRS (b. 1942). British biochemist at the University of Cambridge, structural biologist, and science administrator. Aaron Bodansky (1887–1960). Russian-born American biochemist at the Hospital for Joint Diseases, New York, specializing in the area of calcium metabolism. Paul D. Boyer (1918–2018). American biochemist, at UCLA who studied ATP synthase. Nobel Prize in Chemistry in 1997. Member Natl. Acad. Sci. USA.
The galactic year, GY, is the time it takes the Solar System to revolve once around the galactic core, approximately 250 million years (megaannum or "Ma"). It is a convenient unit for long-term measurements. For example, oceans appeared on Earth after 4 GY, life is detectable at 5 GY, and multicellular organisms first appeared at 15 GY. The age of the Earth is estimated at 20 GY. This use of GY is not to be confused with Gyr for gigayear or Gy for Gray (unit).
Sources: en.wikipedia.org
Examples of landmark, and frequently controversial judgments, include Van Gend en Loos (holding EU law to created a new legal order, and citizens could sue for treaty rights), Mangold v Helm (establishing equality as a general principle of EU law), and Kadi v Commission (confirming international law had to conform with basic principles of EU law). Until 2016, there was the European Union Civil Service Tribunal, which dealt with EU institutions' staff issues.
==== Authorization of ozone therapy ==== In August 2023, Lula sanctioned Law No. 14,648, which authorizes ozone therapy in the national territory. The sanction was countersigned only by the Minister of Justice, Flávio Dino, not receiving the signature of the Minister of Health, Nísia Trindade, who recommended its veto, and it was received as denialism toward science, since the practice lacks scientific proof.
Ian Hamley (born 1965) is a British academic who is the Diamond Professor of Physical Chemistry at the University of Reading. He is a soft matter scientist and physical chemist with research expertise in self-assembling molecules including polymers, peptides and other biomolecules. He has more than 400 published scientific papers. He is the author of 'The Physics of Block Copolymers', 'Introduction to Soft Matter', 'Block Copolymers in Solution', 'Introduction to Peptide Science', and 'Small-Angle Scattering: Theory, Instrumentation, Data and Applications', as well as several edited texts.
=== Immediate effects === Users report feelings of relaxation, sharpness, calmness, and alertness. Those new to smoking may experience nausea, dizziness, coughing and a bad taste in the mouth, and a number of adverse cardio-vascular effects such as increased blood pressure, narrowed arteries, rapid heart beat. Generally, the unpleasant symptoms will eventually vanish over time, with repeated use, as the body builds a tolerance to the chemicals in the cigarettes, such as nicotine. While the functional changes are mostly reversible after quitting, the structural cardiovascular damage is not fully reversible.
=== Influence of timing === As most nutrient supplements feed all living microorganism in the must (whether desirable or not), winemakers will often wait to add the nutrients until they are ready to inoculate the must with their desired S. cerevisiae strain. Producers who are using wild ferments may also wait until after sulfur dioxide additions have killed off unwanted microbes or feed early because they would like the potential complexity that other microbes could add to the wine. When added, the nitrogen is usually in the form of amino acids, combined with vitamins and minerals to help kick start the fermentation.
Sources: en.wikipedia.org
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.
Typical entries list appearance, identity by mass spectrometry, purity by chromatography, water or moisture content, and residual counter-ion. Some certificates also report microbial limits and endotoxin for materials intended for laboratory use. The reported methods and acceptance ranges vary between suppliers.
The peptide is often supplied as an acetate or trifluoroacetate salt, and the counter-ion affects solubility, weight-per-mole calculations, and compatibility with cell assays. Trifluoroacetate can be undesirable in some biological experiments. Knowing the salt form is necessary for accurate concentration determination.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.